Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for SPOM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2005. Start Trial.
Date Value
March 31, 2025 71.61%
December 31, 2024 30.91%
September 30, 2024
June 30, 2024
March 31, 2024
December 31, 2023
September 30, 2023 27.62%
June 30, 2023 24.01%
March 31, 2023 25.14%
December 31, 2022
September 30, 2022
June 30, 2022
March 31, 2022 13.59%
September 30, 2021 16.60%
June 30, 2021 17.82%
March 31, 2021 19.66%
December 31, 2020 17.46%
September 30, 2020 16.50%
June 30, 2020 15.90%
March 31, 2020 15.00%
December 31, 2019
September 30, 2019
June 30, 2019
March 31, 2019 55.29%
December 31, 2018 0.00%
Date Value
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
September 30, 2015 12.59%
June 30, 2015 5.74%
March 31, 2015 27.41%
December 31, 2014 25.34%
September 30, 2014 34.34%
June 30, 2014 95.45%
March 31, 2014 92.86%
December 31, 2013 96.77%
September 30, 2013 18.78%
June 30, 2013 15.00%
March 31, 2013 16.11%
December 31, 2012 7.89%
September 30, 2012 16.91%
June 30, 2012

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Cogstate Ltd. --
TrivarX Ltd. --
Zai Lab Ltd. 54.70%
Viva Biotech Holdings --
Kintor Pharmaceutical Ltd. --